# US 2015/0147399 A1 · Methods and compositions for oral administration of protein and peptide therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147399 A1
- Document ID: US20150147399A1
- Status: Published application
- Kind: A1
- Application number: 14/565,416
- Filed: 2014-12-09
- Published: 2015-05-28
- Earliest claimed: 2008-01-08
- Assignees: Oshadi Drug Administration Ltd.
- Applicants: Oshadi Drug Administration Ltd.
- Inventors: Alexander Vol; Orna Gribova
- Web page: https://patentgrep.com/patent/US20150147399A1

## CPC

- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/21: Interferons {[IFN]}
- A61K 38/23: Calcitonins
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/363: {Fibrinogen}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 7/06: Antianaemics
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.

## Claims

### Claim 1

An oral pharmaceutical composition, comprising an oil having particulate matter suspended therein, wherein the composition is not an emulsion and the particulate matter comprises:
a. a polysaccharide in non-covalent association with silica nanoparticles having a hydrophobic surface, wherein the size of the silica nanoparticles is between 1-100 nanometers and wherein the weight of the polysaccharide is at least twice that of the silica nanoparticles; and
b. a protein or peptide having therapeutic activity, non-covalently associated with said silica nanoparticles and the polysaccharide.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein said polysaccharide is selected from the group consisting of a branched polysaccharide, a linear polysaccharide and a combination thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein said polysaccharide is selected from the group consisting of amylopectin, starch, glycogen, cellulose, dextrin, chitin, alpha glucan, beta glucan, and combinations thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition is anhydrous.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein said size of said silica nanoparticles is between 5-30 nanometers.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein said hydrophobic surface of said silica nanoparticles comprises hydrocarbon moieties.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a structural protein selected from the group consisting of elastin, collagen, keratin, and fibrinogen and combinations thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an amino acid selected from the group consisting of arginine, lysine, glutamic acid, aspartic acid and histidine and combinations thereof.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein said oil comprises a mixture of oils.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein said oil comprises a mixture of oils selected from natural vegetable oils and synthetic analogues thereof.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition further comprises an antioxidant.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein said protein or peptide is selected from a group consisting of: erythropoietin, pituitary growth hormone, glatiramer acetate, apolipoprotein A-1-mimetic peptide, monoclonal antibody against the protein CD20, calcitonin, a tumor necrosis factor (TNF) protein, interferon-alpha, interferon-beta, interferon-gamma, DNase, RNase, and combinations thereof.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the weight of said particulate matter is not more than 25% of the volume of said pharmaceutical composition.

### Claim 14 (depends on 1)

A method of administering a biologically active protein or peptide having a therapeutic activity to a subject in need thereof, comprising orally administering to said subject the pharmaceutical composition of claim 1, thereby administering a protein or peptide to a subject.

### Claim 15

A method of manufacturing a pharmaceutical composition formulated for oral delivery, said method comprising the steps of:
a. mixing silica nanoparticles having a hydrophobic surface, wherein the size of said silica nanoparticles is between 1-100 nanometers, with a polysaccharide, wherein the weight of the polysaccharide is at least twice that of the silica nanoparticles, and whereby said silica nanoparticles form a non-covalent association with said polysaccharide;
b. mixing a protein or peptide having a therapeutic activity with an oil; and
c. mixing said silica nanoparticles and polysaccharide into said oil,
wherein said protein or peptide forms a non-covalent association with said silica nanoparticles and said polysaccharide, wherein said silica nanoparticles, said polysaccharide, and said biologically active protein or peptide are dispersed in said oil and wherein said pharmaceutical composition is not an emulsion.

### Claim 16 (depends on 15)

The method of claim 15, further comprising the step of adding a structural protein to the mixture of silica nanoparticles and polysaccharide.

### Claim 17 (depends on 15)

The method of claim 15, further comprising the step of adding an additional oil component following the addition of said oil.

### Claim 18 (depends on 15)

The method of claim 15, further comprising the step of adding a wax following the addition of said oil.

### Claim 19 (depends on 15)

The method according to claim 15, wherein said protein or peptide is in a lyophilized form prior to step (b).

### Claim 20 (depends on 15)

The method according to claim 15, wherein said protein or peptide is dissolved in an aqueous solution prior to step (b).
